SEATTLE, April 23, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics Inc. (Nohla), a clinical stage biopharmaceutical company focused on the development of universal, off-the-shelf cell therapies to treat cancer and other critical diseases, today announced the hiring of Gary Christianson, PE, as the company’s new Chief Operating Officer (COO). Mr. Christianson will report to Katie Fanning, President and CEO of Nohla.
“Gary is a tremendous addition to Nohla’s leadership team,” said Ms. Fanning. “His expertise in successfully building commercial-ready operations at multiple biopharmaceutical companies will be instrumental as Nohla enters its next phase of growth.”
Mr. Christianson joins Nohla after serving as the Chief Operating Officer at Cascadian Therapeutics, Inc. since 2007. Cascadian Therapeutics was acquired by Seattle Genetics in March 2018. Prior to his role at Cascadian, Mr. Christianson served as the site director for GlaxoSmithKline’s Biologics Unit following its acquisition of Corixa Corp. From 1999 to 2005, Mr. Christianson held positions as vice president, technical operations and general manager overseeing manufacturing and commercial product development. Prior to Corixa, Mr. Christianson served for 12 years overseeing manufacturing and site operations at RIBI ImmunoChem Research, a biopharmaceutical company developing late-stage adjuvant technology. Mr. Christianson received a B.S. in mechanical engineering technology from Montana State University.
“Joining Nohla at this time presents an exciting opportunity to help further establish the company as a leading developer of universal, off-the-shelf cell therapies,” said Gary Christianson, Chief Operating Officer at Nohla. “As a part of the Nohla team, I look forward to advancing the development of its cell therapy programs for patients with significant unmet needs.”
About Nohla Therapeutics
Nohla Therapeutics is a leading developer of off-the shelf cell therapies for the treatment of cancer and other critical diseases. Nohla’s proprietary notch ligand technology platform serves as the foundation for its ongoing clinical, preclinical and discovery programs. The company’s lead product candidate, dilanubicel (NLA101), is currently being evaluated in two ongoing Phase 2 clinical trials in adult and pediatric patients with hematologic malignancies undergoing an allogeneic transplant and adult patients receiving high dose chemotherapy for Acute Myeloid Leukemia. Nohla is also pursuing multiple preclinical and discovery programs focused on CAR progenitor and NK cell therapies, genetically modified stem cells for gene therapy and editing, and cell therapies for immune modulation and induction. More information is available at www.nohlatherapeutics.com.